Lifecore Biomedical, Inc.

Equities

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq 10:30:00 03/07/2024 pm IST 5-day change 1st Jan Change
4.93 USD +4.45% Intraday chart for Lifecore Biomedical, Inc. +4.89% -20.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lifecore Biomedical Agrees to Add 4 Board Members Under 22NW Deal to Avoid Proxy Fight MT
Lifecore Biomedical Announces Cooperation Agreement with 22NW CI
Lifecore Biomedical, Inc. Announces Board Changes CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2000 Dynamic Index CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell Microcap Value Index CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2500 Index CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 3000 Index CI
22NW Fund Submits Shareholder Proposals to Lifecore Biomedical CI
22NW Fund Nominates Candidates to the Board of Lifecore Biomedical CI
Lifecore Biomedical, Inc. and Curation Foods, Inc. Enters into That Certain Seventh Amendment to Credit Agreement CI
Lifecore Biomedical, Inc. Engages BDO USA, P.C. as Independent Registered Public Accounting Firm CI
Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report MT
Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 CI
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024 MT
Top Midday Decliners MT
Lifecore Biomedical Charts Standalone Path, Names Paul Josephs as New CEO Amid Board Changes MT
Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024 CI
Lifecore Biomedical, Inc. Announces Management Changes CI
Tranche Update on Lifecore Biomedical, Inc.'s Equity Buyback Plan announced on July 14, 2010. CI
Lifecore Concludes Strategic Review CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia... Our Logo
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Sector Update: Health Care MT
Lifecore Biomedical Shares Rise Following Expansion of Alcon Contract MT
Alcon, Lifecore Biomedical Extend Contract Manufacturing Agreement MT
Chart Lifecore Biomedical, Inc.
More charts
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.93 USD
Average target price
6 USD
Spread / Average Target
+21.70%
Consensus
  1. Stock Market
  2. Equities
  3. LFCR Stock
  4. News Lifecore Biomedical, Inc.
  5. Lifecore Biomedical Agrees to Add 4 Board Members Under 22NW Deal to Avoid Proxy Fight